Gene expression profiles of de novo diffuse large B-cell lymphoma samples

Gene expression profiling was performed for 21 DLBCL patients. Based on the gene expression profile, each patient was classified into the molecular subclasses: Activated B-cell-like (ABC)/Germinal-center B-cell-like (GCB). A major clinical challenge of diffuse large B-cell lymphoma (DLBCL) is that up to 40% of patients have refractory disease or relapse after initial response to therapy, due to drug-specific molecular resistance. The purpose of the present study was to investigate microRNA (miRNA) involvement in vincristine resistance in DLBCL which was pursued by functional in vitro analysis in DLBCL cell lines and by clinical analysis of DLBCL patients treated with R-CHOP. MiR-155 was documented to be directly linked to vincristine response in DLBCL cell lines and association between miR-155 and ABC/GCB subclasses and clinical outcome was investigated in primary DLBCL samples. 73 primary DLBCL samples were included in this study. Gene expression profiles were determined with Affymetrix HG-U133 Plus2.0 arrays. Gene expression of the 21 samples was normalized together with expression from 52 DLBCL primary clinical samples that have been included in GSE74266 (n=51) and GSE56315 (n=1).